Immunotherapy in gynecological cancers
Open Access
- 28 February 2021
- journal article
- review article
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 2 (1), 48-64
- https://doi.org/10.37349/etat.2021.00033
Abstract
Immunotherapy has changed the natural history of several malignancies that, a decade ago, had a very poor prognosis, such as lung cancer and melanoma. Consequently, many attempts have been done to expand the indications of immunotherapy agents, predominantly immune checkpoint inhibitors (ICIs), in other cancers, including gynecological malignancies. Alongside promising results in cervical and endometrial neoplasms, there are not clear data on the benefit of ICIs as single agent or in combination with antiangiogenic agents in ovarian cancer (OC) and ongoing trials are focusing on combining ICIs with standard chemotherapy or PARP inhibitors. This chapter summarized the evidences of ICIs in gynecological malignancies and report the ongoing trials in cervical, endometrial and OC.Keywords
This publication has 57 references indexed in Scilit:
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJournal of Clinical Oncology, 2017
- Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1JAMA Oncology, 2015
- CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian CancerCancer Immunology Research, 2015
- Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T CellsJournal of Clinical Oncology, 2015
- PD-1, PD-L1 expression in 1599 gynecological cancers: Implications for immunotherapyGynecologic Oncology, 2015
- Adoptive immunotherapy for cancerImmunological Reviews, 2013
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Immunosuppressive Tumor Microenvironment in Cervical Cancer PatientsCancer Microenvironment, 2011
- Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathwaysImmunological Reviews, 2008
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007